ABOS (STOCKS)
Acumen Pharmaceuticals, Inc. Common Stock
$2.530000
+0.060000 (+2.43%)
Prev close: $2.470000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Daniel J. O'Connell
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $160.21M
- Employees
- 52
- P/E (TTM)
- -1.16
- P/B (TTM)
- 1.61
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
6
Strong Buy
5
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-0.44 | $-0.62 | +0.1757 | +28.54% |
|
Jun 2025 (Q2)
|
$-0.68 | $-0.55 | -0.1312 | -23.91% |
|
Mar 2025 (Q1)
|
$-0.48 | $-0.68 | +0.1966 | +29.06% |
|
Dec 2024 (Q4)
|
$-0.62 | $-0.49 | -0.1304 | -26.63% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $4.88M |
| Operating Expenses | $138.23M |
| Research and Development | $118.93M |
| Other Operating Expenses | $19.30M |
| Operating Income/Loss | -$138.23M |
| Income/Loss From Continuing Operations After Tax | -$133.35M |
| Income/Loss From Continuing Operations Before Tax | -$133.35M |
| Net Income/Loss | -$133.35M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$133.35M |
| Net Income/Loss Available To Common Stockholders, Basic | -$133.35M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.22 |
| Diluted Earnings Per Share | -$2.22 |
| Basic Average Shares | 181,694,911 |
| Diluted Average Shares | 181,694,911 |
| Assets | $142.22M |
| Current Assets | $132.15M |
| Noncurrent Assets | $10.07M |
| Fixed Assets | $115.00K |
| Other Non-current Assets | $9.95M |
| Liabilities | $49.05M |
| Current Liabilities | $21.96M |
| Accounts Payable | $682.00K |
| Other Current Liabilities | $21.27M |
| Noncurrent Liabilities | $27.09M |
| Long-term Debt | $27.05M |
| Other Non-current Liabilities | $39.00K |
| Equity | $93.17M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $93.17M |
| Liabilities And Equity | $142.22M |
| Net Cash Flow From Operating Activities | -$123.66M |
| Net Cash Flow From Operating Activities, Continuing | -$123.66M |
| Net Cash Flow From Investing Activities | $137.35M |
| Net Cash Flow From Investing Activities, Continuing | $137.35M |
| Net Cash Flow From Financing Activities | -$45.00K |
| Net Cash Flow From Financing Activities, Continuing | -$45.00K |
| Net Cash Flow | $13.64M |
| Net Cash Flow, Continuing | $13.64M |
| Comprehensive Income/Loss | -$133.76M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$133.76M |
| Other Comprehensive Income/Loss | -$133.76M |